Shionogi Co., Ltd. (Shionogi) and the Global Antibiotic Research and Development Partnership (GARDP) have today announced the execution of a license and technology transfer agreement and, with the Clinton
GARDP, CHAI and Shionogi announce MOU to increase access to antibiotic eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
GARDP, CHAI and Shionogi collaborate to accelerate access to antibiotic for bacterial infections news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Shionogi s Novel Antibiotic, Fetcroja (cefiderocol), Has Been Selected by UK s NICE / NHSE&I as Part of an Antimicrobial Subscription Style Reimbursement Model
Enterobacterales and non-fermenting species such as
P. aeruginosa, A. baumannii, and S. maltophilia, makes them difficult to treat and results in high mortality rates.
7,8 The World Health Organization have identified carbapenem-resistant strains of
Enterobacterales,
A. baumannii as the top priority in the research and development of new antibiotics.
9 Cefiderocol is the first antibiotic to address all three major mechanisms of carbapenem-resistance and is an important new treatment option to address this urgent unmet need.
10
Cefiderocol
Cefiderocol is the world s first siderophore cephalosporin antibiotic with a novel mechanism of entry through the outer membrane of Gram-negative pathogens by using the bacteria s own iron uptake system to gain cell entry, acting like a Trojan horse.